HZNP

Horizon Therapeutics Public Limited Company Ordinary Shares

HZNP

Market cap $26.6B

Overview Fund Activity

Delisted

HZNP was delisted on the 5th of October, 2023.

Back to rankings

About: Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.

Employees: 2,190

Healthcare Drug Manufacturers - General

Financial journalist opinion

Amgen quarterly profit rises 15% as Horizon deal boosts results

Amgen on Tuesday said its adjusted fourth-quarter profit rose 15%, driven by a 20% increase in revenue following the biotechnology company's October acquisition of rare disease drugmaker Horizon Therapeutics.

Cramer names biopharma companies to watch as industry mergers start to pile up

CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.

5 Biotech Acquisition Targets To Accumulate In 2024

Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions.

See News Rankings

Charts implemented using Lightweight Charts™